<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Medical</title>
	<atom:link href="http://www.tapanray.in/tag/medical/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Access Denied, Ethics Demanded: India’s Pharma Detailing at a Turning Point</title>
		<link>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-influence-a-new-era-of-ethical-medical-detailing-in-india</link>
		<comments>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/#comments</comments>
		<pubDate>Fri, 13 Jun 2025 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[limitations]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10913</guid>
		<description><![CDATA[June 11, 2025 — The Economic Times reports that a prominent pharmaceutical industry association has urged the Union Health Ministry to reconsider its directive that bars medical representatives (MRs) from physically meeting doctors in central government hospitals. The industry argues that the move &#8230; <a href="http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Closed Doors, Open Channels: India’s Ban on Medical Reps in Govt Hospitals Reshapes Pharma Engagement</title>
		<link>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement</link>
		<comments>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/#comments</comments>
		<pubDate>Fri, 06 Jun 2025 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[email]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Govt]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[India’s Ban MR]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10909</guid>
		<description><![CDATA[The June 3, 2025, directive from the Directorate General of Health Services (DGHS), banning medical representatives (MRs) from meeting doctors in central government hospitals, marks a pivotal policy shift in India&#8217;s evolving healthcare ecosystem. It signals a firm step toward &#8230; <a href="http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>This New Engagement Model Garners Significant Rewards For Pharma</title>
		<link>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=this-new-engagement-model-garners-significant-rewards-for-pharma</link>
		<comments>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/#comments</comments>
		<pubDate>Mon, 28 Nov 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10731</guid>
		<description><![CDATA[Last year, on July 26, 2021, I wrote in this blog on gaining a competitive edge with Omnichannel pharma marketing Omnichannel pharma marketing. However, from several recent studies, it appears, it’s still remains in a nascent stage. Most players in the industry haven’t &#8230; <a href="http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?</title>
		<link>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shape-of-future-pharma-operations-emerging-a-pragmatic-outlook</link>
		<comments>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/#comments</comments>
		<pubDate>Mon, 12 Apr 2021 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Pragmatic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10468</guid>
		<description><![CDATA[Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, &#8230; <a href="http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating A Unique Patient Experience By Listening To Patients Voice – An Imperative In The New Normal</title>
		<link>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal</link>
		<comments>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 Mar 2021 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers. Covid-19]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[measuring]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[old normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Voice]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10446</guid>
		<description><![CDATA[Acquiring deeper insight on the patient journey through a disease treatment process to create and enhance end-to-end patient experience, never assumed such critical importance, ever in the past. Without this realization, I reckon, even digitalization of any scale in the pharmaceutical &#8230; <a href="http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Pharma To Stay Relevant To Customers In The New Digital World</title>
		<link>http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world</link>
		<comments>http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/#comments</comments>
		<pubDate>Mon, 15 Mar 2021 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand managers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[customer experience managers]]></category>
		<category><![CDATA[customer-relationship]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[employees]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intelligent]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[members]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[old normal]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[realigning]]></category>
		<category><![CDATA[redefine]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[staff]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[work]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10441</guid>
		<description><![CDATA[Covid-19 vaccination has commenced in India on January 16, 2021, as in several other countries of the world. A few million Indians, across the country have already received their first shot, according to media reports. But, this isn’t the endgame of &#8230; <a href="http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time To Audit Pharma’s Doctor-Engagement And Other Digital Strategies</title>
		<link>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies</link>
		<comments>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/#comments</comments>
		<pubDate>Mon, 25 Jan 2021 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[audit]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[e-visits]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[format]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value-delivery]]></category>
		<category><![CDATA[walk the talk]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10400</guid>
		<description><![CDATA[It’s now over a year since the unprecedented global health crisis commenced. In this grueling saga, a silver lining is also visible. It helped pharma industry gain a fascinating operational experience, while navigating through disruptive business changes. The changes in the &#8230; <a href="http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-to-audit-pharmas-doctor-engagement-and-other-digital-strategies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Not To Let Go This Never Before Opportunity To Reposition Itself</title>
		<link>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself</link>
		<comments>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/#comments</comments>
		<pubDate>Mon, 14 Dec 2020 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[competitors]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[holistic]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medical-marketing]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reposition]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[WHD]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10366</guid>
		<description><![CDATA[‘While the COVID-19 pandemic has placed unparalleled demands on modern healthcare systems, the industry’s response has vividly demonstrated its resilience and ability to bring innovations to market quickly.’ This appeared in the McKinsey &#38; Company article – ‘Healthcare innovation: Building on the gains &#8230; <a href="http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid Propels Healthcare Into A Virtual World: A New Growth Driver For Pharma?</title>
		<link>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma</link>
		<comments>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/#comments</comments>
		<pubDate>Mon, 19 Oct 2020 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[consultation]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[e-commerce]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[propels]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[virtual]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10299</guid>
		<description><![CDATA[Amid ongoing Covid pandemic, most discussions on pharma specific ‘digitalization’ initiatives continue to predominantly hover around its traditional business growth drivers. In fact, even before the Covid time, it was no different, in a smaller scale and with a lesser &#8230; <a href="http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Changing Doctors’ Practice Dynamics With Covid-19 And Beyond</title>
		<link>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=changing-doctors-practice-dynamics-with-covid-19-and-beyond</link>
		<comments>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/#comments</comments>
		<pubDate>Mon, 11 May 2020 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[connected]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dynamic]]></category>
		<category><![CDATA[face-to-face]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[practice]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10067</guid>
		<description><![CDATA[Unexpectedly, the answer to an onerous question surfaced just around a year’s time. In my article on this blog, written on April 08, 2019, I raised a question &#8211; “Would ‘Connected Healthcare’ Catch Pharma Players Off-Guard?” Interestingly, an unexpected and abrupt turn of &#8230; <a href="http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
